Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient-Reference-Cited by-同舟云学术

Cytotoxicity of Zardaverine in Embryonal Rhabdomyosarcoma from a Costello Syndrome Patient

Published:2017-04-03 Issue: Volume:7 Page:
ISSN:2234-943X
Container-title:Frontiers in Oncology
language:
Short-container-title:Front. Oncol.

Author:

Cartledge Donna M.,Robbins Katherine M.,Drake Katherine M.,Sternberg Rachel,Stabley Deborah L.,Gripp Karen W.,Kolb E. Anders,Sol-Church Katia,Napper Andrew D.

Funder

National Institute of General Medical Sciences

Publisher

Frontiers Media SA

Subject

Cancer Research,Oncology

Reference41 articles.

1. Tumor predisposition in Costello syndrome;Gripp;Am J Med Genet C Semin Med Genet,2005

2. Germline mutations in HRAS proto-oncogene cause Costello syndrome;Aoki;Nat Genet,2005

3. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation;Gripp;Am J Med Genet A,2006

4. Somatic mosaicism for an HRAS mutation causes Costello syndrome;Gripp;Am J Med Genet A,2006

5. Paternal bias in parental origin of HRAS mutations in Costello syndrome;Sol-Church;Hum Mutat,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic opportunity of phosphodiesterase 3A modulators in myxoid liposarcomas;2022-12-09

2. Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules;Frontiers in Pharmacology;2022-11-24

3. Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death;Cell Chemical Biology;2022-06

4. Pyridazinone Derivatives Limit Osteosarcoma-Cells Growth In Vitro and In Vivo;Cancers;2021-11-28

5. An alkaloid initiates phosphodiesterase 3A–schlafen 12 dependent apoptosis without affecting the phosphodiesterase activity;Nature Communications;2020-06-26